Altimmune (ALT) Short Interest Ratio & Short Volume

Short interest is the volume of Altimmune shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 22,940,000 shares of ALT short. Learn More on Altimmune's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALT shares currently have a short interest ratio of 11.0. Learn More on Altimmune's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Altimmune: Jane Street Group LLC, Wolverine Trading LLC, Walleye Capital LLC, PEAK6 Investments LLC, and Valence8 US LP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Altimmune saw a increase in short interest during the month of October. As of October 31st, there was short interest totaling 22,940,000 shares, an increase of 3.2% from the previous total of 22,230,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Altimmune: Arbutus Biopharma Co. (3.45%), Kamada Ltd. (0.09%), Fulcrum Therapeutics, Inc. (9.21%), BeyondSpring Inc. (8.34%), Unity Biotechnology, Inc. (1.97%), MEI Pharma, Inc. (1.23%), Amphastar Pharmaceuticals, Inc. (12.16%), Apogee Therapeutics, Inc. (18.87%), Mirum Pharmaceuticals, Inc. (14.27%), Centessa Pharmaceuticals plc (2.69%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

Short selling ALT is an investing strategy that aims to generate trading profit from Altimmune as its price is falling. ALT shares are trading up $0.58 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Altimmune occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALT, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALT, twice per month. The most recent reporting period available is October, 31 2024.